acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
character
chang
sputum
product
dyspnoea
cough
aecopd
lead
signific
morbid
among
major
caus
death
worldwid
result
heavi
societ
econom
burden
viral
infect
confirm
caus
aecopd
consid
major
caus
aecopd
hospit
viral
detect
may
influenc
viral
detect
methodolog
sampl
use
assay
sever
previou
studi
conduct
convent
method
includ
viral
cultur
serolog
incid
viral
identif
underestim
compar
molecular
diagnost
method
develop
molecular
diagnost
detect
respiratori
virus
aecopd
easier
accur
induc
sputum
obtain
lower
respiratori
tract
rel
higher
virusdetect
rate
compar
sampl
upper
respiratori
tract
host
inflammatori
respons
import
compon
aecopd
profil
inflammatori
marker
may
use
classifi
airway
inflamm
aecopd
heterogen
inflamm
mani
cytokin
involv
develop
copd
system
level
tumor
necrosi
higher
copd
healthi
control
hc
howev
express
system
inflammatori
marker
wellstudi
viral
aecopd
assess
relationship
aecopd
imbal
inflammatori
antiinflammatori
mediat
may
assist
understand
pathogenesi
aecopd
studi
aim
determin
preval
sever
respiratori
virus
aecopd
detect
distribut
system
inflammatori
marker
patient
diagnos
copd
clinic
symptom
aecopd
requir
hospit
recruit
june
may
jilin
provinci
peopl
hospit
patient
recruit
within
h
present
patient
diagnos
copd
accord
global
initi
chronic
obstruct
lung
diseas
gold
criteria
forc
expiratori
volum
second
forc
vital
capac
fvc
postbronchodil
aecopd
defin
least
two
major
symptom
increas
dyspnoea
enhanc
cough
increas
sputum
product
one
major
one
minor
symptom
nasal
dischargecongest
wheez
sore
throat
cough
least
consecut
day
patient
histori
myocardi
infarct
unstabl
angina
congest
heart
failur
renal
failur
cancer
pulmonari
interstiti
fibrosi
asthma
antiviru
treatment
current
activ
tuberculosi
exclud
addit
copd
patient
unconsci
declin
particip
also
exclud
meanwhil
healthi
neversmok
nonatop
similarag
volunt
histori
respiratori
diseas
underw
sputum
induct
lung
function
assess
accept
routin
checkup
show
clinic
symptom
inflammatori
diseas
induc
sputum
serum
collect
follow
basic
clinic
characterist
record
assess
age
gender
smoke
histori
lung
function
gold
level
written
inform
consent
obtain
patient
prior
recruit
studi
approv
human
research
ethic
committe
jilin
provinci
peopl
hospit
approv
number
sputum
taken
steril
contain
analyz
immedi
microscop
gram
stain
gram
stain
direct
microscop
examin
sputum
incub
hour
inocul
eosin
methylen
blue
agar
blood
agar
brucella
agar
chocol
agar
media
particip
whose
sampl
identifi
bacteri
infect
bacterialvir
coinfect
exclud
recruit
patient
receiv
nebul
salin
second
spirometri
repeat
measur
level
everi
minut
nebul
continu
level
fallen
maximum
minut
sputum
process
within
h
mucu
clump
separ
saliva
use
forcep
minimum
sampl
transfer
test
tube
time
volum
sputolysin
sigma
pool
uk
work
solut
ad
tube
mix
room
temperatur
minut
subsequ
equal
volum
pb
ad
fulli
mix
sampl
filter
centrifug
minut
remov
supernat
cell
pellet
resuspend
lysi
buffer
qiagen
crawley
uk
later
total
nucleic
acid
extract
perform
sampl
suspend
lysi
buffer
ml
venou
blood
collect
heparinlithium
anticoagul
tube
serum
store
later
analysi
inflammatori
marker
sampl
obtain
within
h
enrol
measur
viru
perform
rna
viral
rna
mini
kit
rna
extract
induc
sputum
aecopd
particip
control
thirteen
virus
test
use
rtpcr
abi
onestep
rtpcr
kit
detect
influenza
b
rtpcr
super
iii
onestep
rtpcr
system
taq
dna
polymeras
invitrogen
detect
hmpv
coronaviru
adenoviru
bocaviru
multiplex
rtpcr
super
script
iii
onestep
rtpcr
system
platinum
taq
dna
polymeras
platinum
pcr
super
mix
invitrogen
detect
parainfluenza
rhinoviru
respiratori
syncyti
viru
enteroviru
sputum
use
bacteri
cultur
well
accord
result
particip
divid
viru
posit
aecopd
vp
particip
bacteria
posit
aecopd
bp
particip
virusbacteria
neg
aecopd
vn
particip
coinfect
ci
particip
control
serum
obtain
centrifug
rpm
min
whole
blood
kept
prior
inflammatori
marker
profil
level
cytokin
evalu
quantibodi
human
inflamm
array
ray
biotech
inc
accord
manufactur
instruct
normal
data
test
kolmogorovsmirnov
test
basic
characterist
particip
tabl
differ
two
group
analyz
chisquar
test
student
ttest
cytokin
express
assay
data
normal
distribut
anova
use
evalu
express
differ
cytokin
level
measur
multipl
comparison
method
data
express
mean
valu
standard
error
mean
statist
analysi
perform
use
graph
pad
p
consid
statist
signific
elig
aecopd
patient
june
may
recruit
process
shown
figur
viru
posit
vp
patient
bacteria
posit
bp
patient
coinfect
ci
patient
viru
neg
vn
patient
sever
level
patient
classifi
gold
gold
ii
gold
iii
gold
iv
tabl
particip
vaccin
influenza
previou
year
almost
particip
histori
smoke
current
smoker
current
studi
twelv
healthi
volunt
also
recruit
common
viru
influenza
case
common
bacterium
haemophilu
influenza
tabl
number
aecopd
winter
spring
larger
summer
autumn
figur
p
aecopd
observ
may
juli
vp
observ
march
april
may
juli
baselin
characterist
treatment
recruit
patient
shown
tabl
accord
whether
vp
vn
ci
analysi
suggest
differ
vp
vn
term
runni
congest
nose
discolor
sputum
p
tabl
vp
particip
frequent
fever
versu
p
sore
throat
versu
p
compar
vn
particip
moreov
ci
particip
highest
rate
fever
sore
throat
rate
current
smoker
ci
particip
vp
particip
higher
vn
particip
tabl
vp
particip
report
prior
hospit
aecopd
higher
rate
ci
particip
vn
particip
rate
influenza
vaccin
season
less
vp
particip
compar
vn
particip
p
number
particip
exacerb
symptom
last
day
vp
higher
vn
p
percentag
vp
particip
receiv
treatment
show
differ
compar
vn
particip
p
forti
measur
marker
shown
tabl
result
quantibodi
human
inflamm
array
show
level
vp
ci
higher
hc
p
overexpress
also
observ
vp
vn
p
figur
differ
level
vn
hc
signific
p
level
three
marker
demonstr
differ
vp
ci
p
studi
specif
relat
viral
infect
cytokin
express
aecopd
uncommon
especi
asia
best
knowledg
first
studi
conduct
alpin
region
asia
relat
preval
respiratori
virus
express
cytokin
aecopd
interestingli
viral
distribut
studi
also
quit
differ
studi
influenza
common
respiratori
viru
studi
found
aecopd
subject
tabl
consist
find
common
viru
identifi
influenza
test
viru
posit
nasopharyng
aspir
sampl
august
juli
australia
contrast
report
detect
rate
influenza
hong
kong
prior
influenza
vaccin
modifi
influenza
infect
rate
studi
recruit
aecopd
patient
vaccin
influenza
last
year
among
vaccin
vn
vaccin
ci
howev
particip
vaccin
vp
cohort
higher
vaccin
coverag
influenza
found
lower
preval
influenza
support
comparison
vn
versu
vp
moreov
popul
low
influenza
vaccin
coverag
higher
influenza
detect
rate
none
influenzaposit
patient
receiv
vaccin
previou
year
consid
extrem
low
influenza
vaccin
coverag
total
popul
china
factor
influenzaposit
rate
higher
adult
elderli
attent
paid
rapidli
age
countri
effect
control
influenza
infect
investig
need
confirm
exact
reason
varianc
viral
distribut
viral
detect
rate
find
studi
also
note
odd
phenomenon
rsv
found
viral
aecopd
studi
year
round
studi
conduct
januari
june
china
despit
low
rate
three
case
rsv
infect
found
nasopharyng
sampl
particip
admit
aecopd
inconsist
find
furthermor
rsv
import
caus
viral
infect
lower
respiratori
tract
elderli
highrisk
adult
rank
one
preval
virus
total
aecopd
subject
nineteen
studi
systemat
review
reason
rsv
observ
investig
remain
elus
need
studi
viral
symptom
includ
increas
rhinorrhoea
sore
throat
feverchil
besid
sore
throat
greater
specif
viral
infect
rhinorrhoea
fever
sore
throat
two
major
symptom
differenti
viral
aecopd
nonvir
aecopd
tabl
suggest
diagnosi
viral
symptom
may
elementari
step
accur
casedefinit
viral
aecopd
combin
clinic
symptom
measur
inflammatori
marker
level
markedli
increas
predict
accuraci
compar
diagnosi
clinic
featur
alon
profil
inflammatori
marker
conduct
assess
associ
viral
infect
host
cytokin
respons
aecopd
previou
studi
major
object
detect
investig
type
microorgan
involv
aecopd
less
emphasi
place
proinflammatori
cytokin
found
patient
viral
infect
show
higher
level
without
figur
patient
coinfect
viru
bacteria
also
exhibit
higher
level
neg
microbiolog
result
furthermor
express
marker
show
differ
vn
hc
p
indic
differ
marker
express
might
caus
viral
infect
pleiotrop
acutephas
cytokin
involv
host
immun
respons
infect
reflect
sever
lower
airway
inflamm
higher
level
associ
exacerb
copd
increas
predict
accuraci
viral
infect
combin
clinic
diagnosi
mononuclearphagocyteorigin
cytokin
pleiotrop
effect
innat
host
respons
microb
recruit
inflammatori
cell
site
infect
overexpress
aecopd
potent
chemoattract
contribut
recruit
inflammatori
cell
site
infect
higher
level
report
patient
virusinduc
respiratori
ill
increas
evid
macrophag
orchestr
inflammatori
respons
copd
releas
chemoattract
proteas
higher
level
may
associ
activ
macrophag
influenza
viru
common
viru
studi
induc
activ
macrophag
via
tolllik
receptor
yageta
et
al
found
isol
murin
macrophag
activ
costimul
cigarett
smoke
extract
influenza
viru
respons
influenza
virusinfect
macrophag
produc
larg
amount
cytokin
tissu
macrophag
key
cell
type
respons
product
antivir
immunoreact
cytokin
taken
togeth
conclud
higher
level
inflammatori
marker
might
induc
viral
inflamm
activ
macrophag
might
provid
support
investig
pathogenesi
viral
aecopd
asia
summari
establish
viral
infect
common
alter
viral
profil
aecopd
occur
alpin
china
viral
aecopd
associ
system
immun
respons
involv
suggest
promin
role
macrophag
activ
aecopd
futur
work
defin
clinic
treatment
implic
result
lay
basi
investig
role
immun
system
pathogenesi
develop
aecopd
influenza
preval
viral
pathogen
aecopd
northern
china
patient
viral
aecopd
less
like
receiv
influenza
vaccin
promin
system
immun
respons
involv
may
due
activ
macrophag
caus
viral
infect
import
opportun
investig
aecopd
mechan
develop
better
strategi
manag
prevent
aecopd
associ
viral
infect
